Victoria

Researchers are investigating how forming a family physical activity (PA) identity can promote long-term physical activity in children aged 6 to 12 years. They aim to find out if a family identity formation approach, which includes education and planning, increases children's moderate to vigorous physical activity (MVPA) more than a standard education and planning program after six months. The study also explores if this approach improves children's health-related fitness and how parental support and family dynamics may influence these outcomes. Participants in the social identity group receive standard education and planning plus two extra sessions focused on developing a family PA identity. These sessions include education on PA benefits as a family, creating a family PA action plan, assigning fun family PA roles, and activities like making a family PA t-shirt and displaying family PA photos. The second session focuses on parental support identity using behavior change principles. The study is behavioral and does not involve medication or devices. Families will be involved for six months, with assessments at baseline, 6 weeks, 3 months, and 6 months to measure changes in children's physical activity. Researchers will evaluate child MVPA levels, health-related fitness, and the role of parental support using questionnaires and activity tracking. The study also monitors safety through a Physical Activity Readiness Questionnaire and includes families from specific regions in British Columbia. The total participation includes education, planning, coaching sessions, and follow-up assessments.

This research aims to study the metabolism of cells within the ascites tumor environment in patients with ovarian cancer. It focuses on tracing glucose metabolism using a labeled form of glucose, called [U-13C]glucose, to better understand glucose uptake and metabolic pathways in different cell populations within the ascites fluid. The study is observational and involves ovarian cancer patients who have ascites that requires draining. Participants will receive an intravenous infusion of [U-13C]glucose over a period of up to 5 hours during a standard paracentesis procedure to drain ascites fluid. The infusion starts with 8 grams of labeled glucose in 60 mL administered over 10 minutes, followed by 4 grams in 30 mL over an hour. The process continues until the ascites is drained or 5 hours have passed. Blood glucose levels will be monitored continuously using a glucose monitor throughout the infusion. During the infusion, ascites fluid samples will be collected hourly (up to 5 hours) and kept on ice for analysis. These samples will be studied using flow cytometry and mass spectrometry to assess metabolic states and metabolite profiles. Researchers will measure glucose enrichment in the ascites and compare glucose uptake between cell types. The study involves fitting participants with a continuous glucose monitor before their paracentesis appointment and collecting detailed metabolic data during the procedure.

This research aims to compare different radiation treatments for men newly diagnosed with low volume oligometastatic prostate cancer, which means having fewer than five bone metastases or non-regional lymph node involvement. The study investigates whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as the standard moderately hypofractionated external beam radiotherapy (EBRT). Secondary goals include evaluating progression-free survival, overall survival, and cost-effectiveness, with the hope that ultrahypofractionation will offer similar or better outcomes with less toxicity and better quality of life. Participants will be randomly assigned to one of four treatment groups: standard EBRT delivering 5500 cGy in 20 fractions over 4 weeks; stereotactic body radiotherapy (SABR) delivering 36.25 Gy in 5 fractions over 2 to 5 weeks; permanent seed implant using Iodine-125 seeds implanted in the prostate; or a single high dose rate brachytherapy implant delivering 19 Gy via catheters. Each treatment is delivered at one of four cancer centers, with centers selecting their preferred alternative to the standard EBRT. During the two-year follow-up, participants will have urinary symptoms monitored at six time points using the International Prostate Symptom Score (IPSS). Other quality of life aspects, including urinary, bowel, and sexual function, will be assessed via questionnaires. Researchers will also track progression-free survival, overall survival, and cost-effectiveness. The total participation involves regular assessments over two years to evaluate the treatments' effects and tolerability.

Researchers are evaluating the effects of ALN-APP on the progression of cerebral amyloid angiopathy (CAA), a condition affecting blood vessels in the brain. This phase 2 study aims to assess the safety, tolerability, and pharmacodynamics of ALN-APP in adults with sporadic CAA and Dutch-type CAA, a genetic form of the disease. The study includes a 24-month double-blind treatment period followed by an optional 18-month open-label extension to further explore the treatment's effects. Participants receive either ALN-APP or a placebo, both administered directly into the spinal canal (intrathecally). The initial 24-month period is conducted in a double-blind manner where neither the participants nor the researchers know who receives the treatment or placebo. After this, participants may join the open-label extension phase where everyone receives ALN-APP. This design helps to monitor the drug's impact over a long period. During the study, participants will undergo brain scans using magnetic resonance imaging (MRI) to measure new microbleeds in the brain, which are a marker of disease progression. Researchers will also monitor safety and drug effects through various assessments. The total participation time, including screening, treatment, and follow-up, can last up to 50 months, allowing for thorough observation of treatment outcomes and safety.

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3, randomized, placebo-controlled study to see if it can reduce the risk of major adverse cardiovascular events (MACE-PLUS) in adults with established atherosclerotic cardiovascular disease (ASCVD) or those at high risk for a first ASCVD event. The study compares AZD0780 to a placebo and monitors participants from randomization until the primary analysis censoring date, followed by a final study closure visit. Participants will be randomly assigned to receive either oral AZD0780 or an oral placebo once daily. The treatment period lasts until the primary analysis censoring date, after which a study closure visit will occur. The study is event-driven and designed to assess the time to the first major cardiovascular event during treatment. During the study, participants will be closely monitored with various assessments to evaluate cardiovascular outcomes and safety over approximately 54 months. Researchers will track the time to first event of any component of MACE-PLUS and collect data to assess the effect of AZD0780 compared to placebo. The study includes regular visits and evaluations to ensure participant safety and adherence to treatment.

Researchers are evaluating two types of radiation treatments for women with small, node-negative breast cancer (3 cm or smaller) after breast-conserving surgery. The study aims to find out if partial breast irradiation (PBI) given once a day over one week is not worse than whole breast irradiation (WBI) in preventing cancer from coming back locally and if it leads to better cosmetic outcomes as assessed by patients three years after treatment. This is a phase 3 randomized trial focusing on the comparison of these two radiation approaches. Participants will be randomly assigned to receive either PBI or WBI. Both treatments deliver a total radiation dose of 26 Gy divided into 5 daily sessions over 5 to 7 days (up to 8 days allowed due to holidays). The radiation is carefully targeted to the appropriate breast area, and the study is single-blinded so that patients do not know which treatment they receive to avoid bias in cosmetic assessments. Treatment planning includes using CT imaging and surgical markers for accurate delivery. During the study, participants will be monitored annually for five years to check for local cancer recurrence. Cosmetic outcomes will be assessed by patients themselves at three and five years post-treatment. Other evaluations include tumor characteristics and receptor status, and treatment safety will be observed. The total participation involves follow-up over several years to understand long-term effects of the treatments.

Researchers are evaluating ziltivekimab as a treatment for people living with heart failure and inflammation. This Phase 3 study compares ziltivekimab to a placebo in participants with heart failure who have mild to preserved ejection fraction and systemic inflammation. The study aims to assess the effect of ziltivekimab on cardiovascular death, heart failure hospitalization, or urgent heart failure visits over a period of up to 4 years. Participants will receive monthly injections of either ziltivekimab or a placebo using a pre-filled syringe or a pen-injector. The study medication is administered subcutaneously once a month for up to 4 years. The trial includes up to 20 clinic visits during which participants will be monitored and assessed. During the study, participants will use a study app on their phone to record all injections and complete questionnaires. Researchers will monitor participants for key outcomes like cardiovascular events and heart failure episodes from the time of randomization until the end of the study. Safety and health status will be regularly evaluated throughout the study period, which may last up to 48 months.

Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared to pembrolizumab with pemetrexed and either carboplatin or cisplatin. The study focuses on adults with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has a specific KRAS G12C mutation. This is a Phase III trial aiming to improve first-line treatment options for these patients. Participants will receive one of two treatment combinations. One group will take divarasib orally once daily along with pembrolizumab given through an intravenous infusion every three weeks. The other group will receive pembrolizumab with pemetrexed and either carboplatin or cisplatin, all administered by intravenous infusion every three weeks. Treatment schedules and dosages are carefully monitored during the study. Throughout the study, participants will be regularly assessed for progression-free survival and overall survival, with follow-up lasting up to approximately five years. Researchers will perform various evaluations including tumor measurements and safety monitoring. This long-term observation helps to understand the treatments' effects and safety over time, supporting informed decisions for future lung cancer therapies.

This trial investigates whether eptinezumab can reduce the number of migraine days in children and teenagers aged 6 to 17 with episodic migraine. The study focuses on pediatric participants who have had migraine headaches for at least six months, aiming to evaluate the preventive treatment potential of this medication. This is a Phase 3 randomized, double-blind, placebo-controlled study designed to assess both the effectiveness and safety of eptinezumab given intravenously. Participants will receive either eptinezumab or a placebo, both administered as a solution through an infusion. The study includes a screening period where migraine and headache frequency are recorded using an electronic diary. The main measurement is the change from baseline in the average number of monthly migraine days over the first 12 weeks of treatment. During the study, participants and their caregivers will complete headache diaries to track migraine occurrences. Researchers will monitor migraine frequency and evaluate safety throughout the trial. The primary outcome is the difference in migraine days per month compared to the start of the study, assessed over the 12-week treatment period. This study helps understand how well eptinezumab may prevent episodic migraine in the pediatric population.

This research aims to evaluate the safety and effectiveness of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a topoisomerase inhibitor, compared to the treatment of physician's choice (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, or capecitabine). The study focuses on patients with previously untreated, locally advanced, recurrent inoperable, or metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, HER2-negative breast cancer who are not eligible for anti-PD(L)1 or endocrine therapies. The trial is conducted in two phases, phase 2 and phase 3, to thoroughly assess these treatments.